Pharmacological treatment of the basic defect in cystic fibrosis

Citations Over Time

Abstract

Cystic fibrosis (CF) is a genetic disease due to a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel in epithelial cells. There are about 1900 mutations, divided in several groups, for example, stop mutations, mutations affecting the permeability of the channel, and mutations in which the mutated CFTR is recognized as abnormal and destroyed. Pharmacological treatment has become possible for stop mutations (about 10% of the patients), and for a rare mutation affecting channel permeability. For the majority of patients, however, that have a mutation in which the mutated CFTR is destroyed on its way to the cell membrane, research is still in progress, although a number of compounds have been identified that (at least partly) corrects the error in chloride transport.

Related Papers

• → Effect of Deleting the R Domain on CFTR-Generated Chloride Channels(1991)272 cited
• → The Chloride Channel ClC-4 Co-localizes with Cystic Fibrosis Transmembrane Conductance Regulator and May Mediate Chloride Flux across the Apical Membrane of Intestinal Epithelia(2002)57 cited
• → ClC AND CFTR CHLORIDE CHANNEL GATING(1998)69 cited
• → Cystic Fibrosis Transmembrane Conductance Regulator And The Outwardly Rectifying Chloride Channel: A Relationship Between Two Chloride Channels Expressed In Epithelial Cells(2000)39 cited
• → Effects of Cystic Fibrosis and Congenital Bilateral Absence of the Vas Deferens–Associated Mutations on Cystic Fibrosis Transmembrane Conductance Regulator–Mediated Regulation of Separate Channels(2000)10 cited